药物遗传学与年龄相关性黄斑变性
Pharmacogenetics and age-related macular degeneration.
作者信息
Schwartz Stephen G, Brantley Milam A
机构信息
Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, 311 9th Street North, No. 100, Naples, FL 34102, USA.
出版信息
J Ophthalmol. 2011;2011:252549. doi: 10.1155/2011/252549. Epub 2011 Oct 20.
Abstract
Pharmacogenetics seeks to explain interpatient variability in response to medications by investigating genotype-phenotype correlations. There is a small but growing body of data regarding the pharmacogenetics of both nonexudative and exudative age-related macular degeneration. Most reported data concern polymorphisms in the complement factor H and age-related maculopathy susceptibility 2 genes. At this time, the data are not consistent and no definite conclusions may be drawn. As clinical trials data continue to accumulate, these relationships may become more apparent.
摘要
药物遗传学旨在通过研究基因型与表型的相关性来解释患者对药物反应的个体差异。关于非渗出性和渗出性年龄相关性黄斑变性的药物遗传学，虽有少量但不断增长的数据。大多数报告的数据涉及补体因子H和年龄相关性黄斑病变易感性2基因的多态性。目前，数据并不一致，无法得出明确结论。随着临床试验数据不断积累，这些关系可能会变得更加明显。
相似文献
1
Pharmacogenetics and age-related macular degeneration.药物遗传学与年龄相关性黄斑变性
J Ophthalmol. 2011;2011:252549. doi: 10.1155/2011/252549. Epub 2011 Oct 20.
2
Hot Topics in Pharmacogenetics of Age-Related Macular Degeneration.年龄相关性黄斑变性的药物遗传学热点话题
Curr Pharm Des. 2017;23(4):547-550. doi: 10.2174/1381612822666161208114847.
3
Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.遗传和非遗传风险因素的联合作用影响雷珠单抗治疗渗出性年龄相关性黄斑变性的疗效。
Acta Ophthalmol. 2015 Sep;93(6):e451-7. doi: 10.1111/aos.12587. Epub 2014 Nov 17.
4
Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration.渗出性年龄相关性黄斑变性抗VEGF治疗反应的药物基因组学
Retina. 2015 Mar;35(3):381-91. doi: 10.1097/IAE.0000000000000466.
5
Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration.白细胞介素 8 启动子多态性预测渗出性年龄相关性黄斑变性对贝伐单抗治疗的初始反应。
Retina. 2013 Oct;33(9):1815-27. doi: 10.1097/IAE.0b013e318285cf92.
6
Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.补体因子H和LOC387715基因分型与渗出性年龄相关性黄斑变性对玻璃体内注射贝伐单抗反应的关联
Ophthalmology. 2007 Dec;114(12):2168-73. doi: 10.1016/j.ophtha.2007.09.008.
7
Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.补体因子 H Y402H 基因多态性与渗出性年龄相关性黄斑变性对玻璃体内贝伐单抗的反应。
Acta Ophthalmol. 2011 Jun;89(4):e344-9. doi: 10.1111/j.1755-3768.2010.02080.x. Epub 2011 Jan 14.
8
Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab.雷珠单抗和贝伐单抗治疗年龄相关性黄斑变性的反应的药物遗传学
Semin Ophthalmol. 2013 Sep-Nov;28(5-6):355-60. doi: 10.3109/08820538.2013.825292. Epub 2013 Sep 6.
9
[Age-related Macular Degeneration in the Japanese].[日本的年龄相关性黄斑变性]
Nippon Ganka Gakkai Zasshi. 2016 Mar;120(3):163-88; discussion 189.
10
Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network.美国年龄相关性黄斑变性发病率的种族差异：一项管理式医疗网络的纵向分析。
Am J Ophthalmol. 2011 Aug;152(2):273-282.e3. doi: 10.1016/j.ajo.2011.02.004. Epub 2011 Jun 22.
引用本文的文献
1
Complement System and Age-Related Macular Degeneration: Implications of Gene-Environment Interaction for Preventive and Personalized Medicine.补体系统与年龄相关性黄斑变性：基因-环境相互作用对预防医学和个体化医学的影响。
Biomed Res Int. 2018 Aug 26;2018:7532507. doi: 10.1155/2018/7532507. eCollection 2018.
2
Genetics and age-related macular degeneration: a practical review for the clinician.遗传学与年龄相关性黄斑变性：临床医生实用综述
Clin Ophthalmol. 2016 Jul 4;10:1229-35. doi: 10.2147/OPTH.S109723. eCollection 2016.
3
Pharmacogenetics and nutritional supplementation in age-related macular degeneration.年龄相关性黄斑变性中的药物遗传学与营养补充
Clin Ophthalmol. 2015 May 15;9:873-6. doi: 10.2147/OPTH.S84155. eCollection 2015.
4
A comparative analysis of C57BL/6J and 6N substrains; chemokine/cytokine expression and susceptibility to laser-induced choroidal neovascularization.C57BL/6J和6N亚系的比较分析；趋化因子/细胞因子表达及对激光诱导脉络膜新生血管形成的易感性
Exp Eye Res. 2014 Dec;129:18-23. doi: 10.1016/j.exer.2014.10.005. Epub 2014 Oct 13.
5
Complement inhibitors for age-related macular degeneration.用于年龄相关性黄斑变性的补体抑制剂
Cochrane Database Syst Rev. 2014 Jan 15;2014(1):CD009300. doi: 10.1002/14651858.CD009300.pub2.
6
The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.补体因子H（CFH）基因多态性对玻璃体内注射雷珠单抗治疗年龄相关性黄斑变性（AMD）疗效的影响。
Mol Vis. 2013 Dec 20;19:2571-8. eCollection 2013.
7
Molecular imaging of retinal disease.视网膜疾病的分子成像。
J Ocul Pharmacol Ther. 2013 Mar;29(2):275-86. doi: 10.1089/jop.2012.0279. Epub 2013 Feb 19.
8
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).与年龄相关性黄斑变性相关基因的药物遗传学：比较 AMD 治疗试验 (CATT)。
Ophthalmology. 2013 Mar;120(3):593-599. doi: 10.1016/j.ophtha.2012.11.037. Epub 2013 Jan 18.
本文引用的文献
1
CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.CFH、VEGF 和 HTRA1 启动子基因型可能影响新生血管性年龄相关性黄斑变性患者对玻璃体内雷珠单抗治疗的反应。
Br J Ophthalmol. 2012 Feb;96(2):208-12. doi: 10.1136/bjo.2010.193680. Epub 2011 May 10.
2
Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.玻璃体内注射贝伐单抗与玻璃体内注射贝伐单抗联合曲安奈德治疗新生血管性年龄相关性黄斑变性：一项随机临床试验的 6 个月结果。
Retina. 2011 Oct;31(9):1819-26. doi: 10.1097/IAE.0b013e31820d58f2.
3
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.基因与新生血管性年龄相关性黄斑变性患者对玻璃体内雷珠单抗治疗反应的相关性。
Invest Ophthalmol Vis Sci. 2011 Jul 1;52(7):4694-702. doi: 10.1167/iovs.10-6080.
4
Risk- and non-risk-associated variants at the 10q26 AMD locus influence ARMS2 mRNA expression but exclude pathogenic effects due to protein deficiency.10q26AMD 位点的风险相关和非风险相关变异影响 ARMS2 mRNA 表达，但排除因蛋白缺乏导致的致病性影响。
Hum Mol Genet. 2011 Apr 1;20(7):1387-99. doi: 10.1093/hmg/ddr020. Epub 2011 Jan 20.
5
Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD.载脂蛋白 E 基因变异与新生血管性年龄相关性黄斑变性抗血管内皮生长因子治疗后的改善结局相关。
Invest Ophthalmol Vis Sci. 2011 Jun 8;52(7):4072-9. doi: 10.1167/iovs.10-6550.
6
Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.补体因子 H Y402H 基因多态性与渗出性年龄相关性黄斑变性对玻璃体内贝伐单抗的反应。
Acta Ophthalmol. 2011 Jun;89(4):e344-9. doi: 10.1111/j.1755-3768.2010.02080.x. Epub 2011 Jan 14.
7
Pigment epithelium-derived factor gene polymorphisms in exudative age-related degeneration in a chinese cohort.中国人群渗出型年龄相关性黄斑变性中色素上皮衍生因子基因多态性
Curr Eye Res. 2011 Jan;36(1):60-5. doi: 10.3109/02713683.2010.524343.
8
9
The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application.补体系统对年龄相关性黄斑变性发病机制的意义——当前的证据及其向临床应用的转化。
Graefes Arch Clin Exp Ophthalmol. 2011 Feb;249(2):163-74. doi: 10.1007/s00417-010-1568-6. Epub 2010 Dec 3.
10
Genotype at polymorphism rs11200638 and HTRA1 expression level.多态性rs11200638的基因型与HTRA1表达水平。
Arch Ophthalmol. 2010 Nov;128(11):1491-3. doi: 10.1001/archophthalmol.2010.256.
Zotero 插件